Compare · HLTH vs RVTY
HLTH vs RVTY
Side-by-side comparison of Cue Health Inc. (HLTH) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HLTH and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 15.5x HLTH ($1.12B).
- RVTY has hit the wire 7 times in the past 4 weeks while HLTH has been quiet.
- RVTY has more recent analyst coverage (23 ratings vs 5 for HLTH).
- Company
- Cue Health Inc.
- Revvity Inc.
- Price
- $27.26-0.84%
- $152.62-1.34%
- Market cap
- $1.12B
- $17.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 7
- Recent ratings
- 5
- 23
Latest HLTH
- Tema Launches Healthcare AI ETF (HLTH)
- Made Scientific Strengthens Board to Support Scale-Up and Commercial Readiness in Cell Therapy Manufacturing
- Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Nasdaq Surges 100 Points; US Private Sector Adds 152,000 Jobs For May
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
- Why American Eagle Outfitters Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Dow Tumbles Over 300 Points; Dollar General Earnings Top Views
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery